Alemtuzumab in chronic lymphocytic leukemia: Final results of a large observational multicenter study in mostly pretreated patients

Annals of Hematology

Volumn 93, Issue 2, 2014, Pages 267-277

  Fiegl, M ^a   Stauder, R ^a   Steurer, M ^a   Mian, M ^a   Hopfinger, G ^b   Brychtova, Y ^c   Skrabs, C ^b   Zabernigg, A ^b   Schmid, F ^b   Haslbaur, F ^b   Winder, G ^b   Walder, A ^b   Lang, A ^b   Voskova, D ^d   Greil, R ^e   Mayer, J ^c   Gastl, G ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d KEPLER UNIVERSITY HOSPITAL   (Austria)

^e UNIVERSITY OF SALZBURG   (Austria)

Author keywords

Alemtuzumab; B cell prolymphocytic leukemia; B PLL; Chronic lymphocytic leukemia; CLL; Observational study

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; FOLLOW UP; HUMAN; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKEMIA, PROLYMPHOCYTIC, B-CELL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RETROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKEMIA, PROLYMPHOCYTIC, B-CELL; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84895057476     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1966-z     Document Type: Article

References (41)

1. Keating MJ, Flinn I, Jain V et al (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99:3554-3561
2. Rai KR, Freter CE, Mercier RJ et al (2002) Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 20:3891-3897
3. Fiegl M, Falkner A, Hopfinger G et al (2006) Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria. Cancer 107:2408-2416
4. Rieger K, Von Grünhagen U, Fietz T et al (2004) Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia - change of regimen needed? Leuk Lymphoma 45:345-349
5. Karlsson C, Norin S, Kimby E et al (2006) Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation. Leukemia 20:2204-2207
6. Osterborg A, Dyer MJ, Bunjes D et al (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 15:1567-1574
7. Ferrajoli A, O'Brien SM, Cortes JE et al (2003) Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 98:773-778
8. Moreton P, Kennedy B, Lucas G et al (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23:2971-2979
9. Stilgenbauer S, Zenz T, Winkler D et al (2009) Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 27:3994-4001
10. Hillmen P, Skotnicki AB, Robak T et al (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25:5616-5623
11. Rai K, Keating MJ, Coutre S et al (2002) Patients with refractory B-CLL and T-PLL treated with alemtuzumab (Campath) on a compassionate basis. A report on efficacy and safety of CAM511 trial. Blood 100:(Abstr 3165)
12. Lozanski G, Heerema NA, Flinn IW et al (2004) Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103:3278-3281
13. Osuji NC, Del Giudice I, Matutes E et al (2005) The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica 90:1435-1436
14. Wickramanayake PD, Köppler H, Rohrberg R et al (2005) Use of alemtuzumab (MabCampath®) is safe and effective in an outpatient setting: interim analysis of a postmarketing surveillance. Onkologie 28(suppl3): 86 (Abstract 253)
15. Laros-van Gorkom BA, Huisman CA, Wijermans PW, Schipperus MR (2007) Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands. Neth J Med 65:333-338
16. Hui D, Lam W, Toze C et al (2008) Alemtuzumab in clinical practice: a British Columbia experience. Leuk Lymphoma 49:218-226
17. Doubek M, Jungová A, Brejcha M, Panovská A, Brychtová Y, Pospísil Z, Mayer J (2009) Alemtuzumab in chronic lymphocytic leukemia treatment: retrospective analysis of outcome according to cytogenetics. Vnitr Lek 55:549-554
18. Cortelezzi A, Gritti G, Laurenti L et al (2011) An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients. Br J Haematol 156:481-489
19. Dearden CE, Matutes E, Cazin B et al (2001) High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 98:1721-1726
20. Bowen AL, Zomas A, Emmett E, Matutes E, Dyer MJ, Catovsky D (1997) Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol 96:617-619
21. Chaar BT, Petruska PJ (2007) Complete response to alemtuzumab in a patient with B prolymphocytic leukemia. Am J Hematol 82:417
22. Dearden C (2012) How I treat prolymphocytic leukemia. Blood 120:538-551
23. Fiegl M, Erdel M, Tinhofer I et al (2010) Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories. Ann Oncol 21:2410-2419
24. Fiegl M, Falkner F, Steurer M et al (2011) Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients. Ann Hematol 90:1083-1091
25. Osterborg A, Foà R, Bezares RF et al (2009) Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 23:1980-1988
26. Cheson BD, Bennett JM, Grever M et al (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87:4990-4997
27. Fan L, Wang L, Zhang R et al (2012) Richter transformation in 16 of 149 Chinese patients with chronic lymphocytic leukemia. Leuk Lymphoma 53:1749-1756
28. Rossi D, Cerri M, Capello D et al (2008) Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol 142:202-215
29. Tsimberidou AM, O'Brien S, Khouri I et al (2006) Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 24:2343-2351
30. Cortelezzi A, Pasquini MC, Gardellini A et al (2009) Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia 23:2027-2033
31. Bezares RF, Stemelin G, Diaz A et al (2011) Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis. Leuk Lymphoma 52:1936-1941
32. Montillo M, Tedeschi A, Petrizzi VB et al (2011) An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia. Blood 118:4079-4085
33. Gritti G, Reda G, Maura F et al (2012) Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Leuk Lymphoma 53:424-429
34. Hisada M, Biggar RJ, Greene MH et al (2001) Solid tumors after chronic lymphocytic leukemia. Blood 98:1979-1981
35. Dalia S, Chavez JC, Domingo G et al (2012) Incidence of second and secondary malignancies in patients with CLL: a single institution experience. J Clin Oncol 30(suppl; abstr 6568)
36. Puttarajappa C, Yabes J, Bei L et al (2013) Cancer risk with alemtuzumab following kidney transplantation. Clin Transplant 27:E264-E271
37. Hercher C, Robain M, Davi F et al (2001) A multicentric study of 41 cases of B-prolymphocytic leukemia: two evolutive forms. Leuk Lymphoma 42:981-987
38. Shvidel L, Shtalrid M, Bassous L, Klepfish A, Vorst E, Berrebi A (1999) B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course. Leuk Lymphoma 33:169-179
39. Arnason JE, Brown JR (2011) Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2011:119-120
40. Pettitt AR, Jackson R, Carruthers S et al (2012) Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol 30:1647-1655
41. Döhner H, Stilgenbauer S, Benner A et al (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916